Study Stopped
Zero accrual
Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer
Evaluating Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements for Oncologic Patients - A Cross-Sectional Survey Study at Norris Comprehensive Cancer Center
3 other identifiers
observational
N/A
1 country
1
Brief Summary
This trial studies nutritional preferences and product accessibility in oral nutritional supplements in participants with breast, colorectal, upper gastrointestinal, or prostate cancer. Learning what participants like and dislike about their current or past used nutritional supplements may help doctor know how to improve them.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Aug 2018
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 8, 2018
CompletedFirst Posted
Study publicly available on registry
June 20, 2018
CompletedStudy Start
First participant enrolled
August 30, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 24, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
September 24, 2020
CompletedDecember 14, 2020
December 1, 2020
2.1 years
June 8, 2018
December 10, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
The way patients with cancer choose and obtain nutritional supplements to support medical management
Data from the oral nutritional supplement survey that examines quality, quantity, access and affordability of oral nutrional supplements will be summarized.
Up to 1 year
Secondary Outcomes (1)
Associations of gastrointestinal side effects with specific diagnoses and respective medical therapies
Up to 1 year
Study Arms (1)
Observational (interview, survey)
Participants attend an interview over 15 minutes and complete surveys.
Interventions
Eligibility Criteria
Patients with the diagnosis of breast cancer, colorectal cancer, upper gastrointestinal cancer (including gastric, pancreatic, and cholangiocarcinoma), and prostate cancer who are seen at the USC facilities will be screened and recruited for this study.
You may qualify if:
- Ability to comprehend English (both reading and writing)
- Subjects in the inpatient and outpatient setting with the diagnosis of breast cancer, colorectal cancer, upper gastrointestinal cancer (including gastric, pancreatic, and cholangiocarcinoma), or prostate cancer
- Receiving chemotherapy, biologic, or hormonal therapy in the University of Southern California (USC) Norris Comprehensive Cancer Center Day Hospital
- Ability to understand and the willingness to sign a written informed consent
You may not qualify if:
- Patients with a mental disability that makes them unable to understand and respond to the questions
- Patients with reported non-oncologic associated deficits in taste and smell
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Southern Californialead
- National Cancer Institute (NCI)collaborator
Study Sites (1)
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jacek Pinski, MD
University of Southern California
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 8, 2018
First Posted
June 20, 2018
Study Start
August 30, 2018
Primary Completion
September 24, 2020
Study Completion
September 24, 2020
Last Updated
December 14, 2020
Record last verified: 2020-12